Skip to main content
Premium Trial:

Request an Annual Quote

ImmunArray Lands $10M in Private Financing

NEW YORK (GenomeWeb) – Molecular diagnostics firm ImmunArray announced that it has received a $10 million Series B investment from private investment firm Exigent Capital.

Other details of the financing were not disclosed.

The firm, which is based in Israel and Virginia, markets blood-based tests based on its iChip antibody-detecting microarray technology. So far, it has developed a six-biomarker panel for ruling out systemic lupus erythematosus and is developing tests for traumatic brain injury and immuno-oncology. The iChip platform can print proteins and peptides, short sequences of nucleotides and DNA, as well as cell surface receptors, cytokines, chemokines, and even lipid or carbohydrate-based molecules.

The funding will help the firm "accelerate and expand our commercial infrastructure, widen our reach into lupus-related products, and broaden our work into other autoimmune diseases," said CEO Donna Edmonds in a statement, adding that the money would help the firm move toward commercializing its brain injury tests.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.